In a significant advancement for energy storage technology, U.S. Army scientists have unveiled a novel surface treatment ...

U.S. Army scientists have developed a new surface treatment that could lead to more efficient and longer-lasting batteries.

"This enables us strategic flexibility post data readouts expected later this year for our INBRX-109 and INBRX-106 programs," said Kelly Deck, Chief Financial Officer of Inhibrx. "Oxford has been a ...

“Commonly known as the stomach flu, norovirus has been around forever, and has become the leading cause of gastroenteritis or ...

AI Proteins, Inc., a biotechnology company that utilizes computational de novo protein design to create therapeutic miniproteins, announced today it has entered into a Collaborative Research Agreement ...

New trials in three new indications have been initiated with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent ...

INBRX-106 is under clinical development by Inhibrx Biosciences and currently in Phase II for Triple-Negative Breast Cancer (TNBC).

Interdisciplinary Nanoscience Center, Aarhus University, Gustav Wieds Vej 14, Aarhus C 8000, Denmark The Centre for Cellular Signal Patterns (CELLPAT), Gustav Wieds Vej 14, Aarhus C 8000, Denmark ...

Every product was carefully curated by an Esquire editor. We may earn a commission from these links. Here’s how we test products and why you should trust us. Daniel Craig snowballing Drew ...